Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
159.65
+3.12 (+1.99%)
Streaming Delayed Price
Updated: 10:37 AM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
August 03, 2021
From
BeiGene, Ltd.
Via
Business Wire
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
July 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients
July 30, 2021
BeiGene Ltd (NASDAQ: BGNE) announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to...
Via
Benzinga
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
July 29, 2021
From
BeiGene, Ltd.
Via
Business Wire
Why BeiGene Stock Soared Today
July 28, 2021
A regulatory filing gave a sneak peek at the company's second-quarter sales.
Via
The Motley Fool
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Chinese Stock Crash
July 26, 2021
For a second week in a row, we saw a big drop in stocks on Monday, while the Delta virus variant was blamed for the selloff last week, this week the cause is a big Beijing regulatory crackdown on...
Via
Talk Markets
62 Biggest Movers From Yesterday
July 29, 2021
Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma
July 26, 2021
Health Canada has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at...
Via
Benzinga
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
July 26, 2021
From
BeiGene, Ltd.
Via
Business Wire
Yellow Card
July 12, 2021
The price of oil fell about 1% today.
Via
Talk Markets
BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients
July 09, 2021
The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The...
Via
Benzinga
BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
July 09, 2021
From
BeiGene, Ltd.
Via
Business Wire
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
July 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
July 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
July 07, 2021
From
BeiGene, Ltd.
Via
Business Wire
PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer
July 07, 2021
PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership...
Via
Benzinga
Fireworks Display
July 05, 2021
The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.
Via
Talk Markets
Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market
July 03, 2021
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Is This Chinese Biopharma Stock Still a Buy?
June 28, 2021
The pharmaceutical company had a solid first quarter and boasts a nice pipeline.
Via
The Motley Fool
Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development
June 26, 2021
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. The company is developing its own products and...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
June 23, 2021
From
BeiGene, Ltd.
Via
Business Wire
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
June 21, 2021
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Chicago Fed National...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
5 Stocks To Watch For June 21, 2021
June 21, 2021
Some of the stocks that may grab investor focus today are: Amazon.com, Inc. (NASDAQ: AMZN) will remain in focus with the company’s two-day Prime shopping event beginning...
Via
Benzinga
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
June 19, 2021
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong...
Via
Talk Markets
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
June 18, 2021
From
BeiGene
Via
Business Wire
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
June 17, 2021
From
BeiGene, Ltd.
Via
Business Wire
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
June 12, 2021
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
June 11, 2021
BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (...
Via
Benzinga
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
June 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
June 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.